clinical trial · NCT06588153
A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China
Amgen·phase4·recruiting·n = 100
Glucocorticoid-induced OsteoporosisProlia®
brief summary
The main objective of this study is to evaluate the efficacy of Prolia® in improving bone mass density (BMD) of lumbar spine at month 12.
started
May 24, 2025
primary completion
May 24, 2027
completion
May 24, 2027
last updated
Mar 25, 2026
official title
A Phase 4 Single-arm Open-label Study for the Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol